Table 2

Patients with GP-coded atrial fibrillation prior to first stroke

GP-coded atrial fibrillationMaleFemaleTotal
n%95% CIn%95% CIn%95% CI
Number of patients (% of cohort)14119.8207211.6348310.8
Baseline characteristics
 Mean (SD) age77.3 (9.8)(76.8 to 77.8)82.4 (8.7)(82.0 to 82.8)80.3 (9.5)(80.0 to 80.6)
CHADS2 score prior to initial stroke (% of AF patients)
 021715.4(13.5 to 17.3)1276.1(5.1 to 7.2)3449.9(8.9 to 10.9)
 160142.6(40.0 to 45.2)73035.2(33.2 to 37.3)133138.2(36.6 to 39.8)
 243030.5(28.1 to 32.9)87742.3(40.2 to 44.5)130737.5(35.9 to 39.1)
 31087.7(6.3 to 9.0)21310.3(9.0 to 11.6)3219.2(8.3 to 10.2)
 4493.5(2.5 to 4.4)1115.4(4.4 to 6.3)1604.6(3.9 to 5.3)
 560.4(0.1 to 0.8)140.7(0.3 to 1.0)200.6(0.3 to 0.8)
Treatments in year prior to initial stroke (at least 2 prescriptions) (% of AF patients)
 Anticoagulants41529.4(27.0 to 31.8)46122.2(20.5 to 24.0)87625.2(23.7 to 26.6)
 Antiplatelet drugs66847.3(44.7 to 49.9)112854.4(52.3 to 56.6)179651.6(49.9 to 53.2)
Follow-up
 Died within 56 days of initial stroke (% of AF patients)26418.7(16.7 to 20.7)55426.7(24.8 to 28.6)81823.5(22.1 to 24.9)
 Survived at least 56 days following initial stroke (% of AF patients)114781.3(79.3 to 83.3)151873.3(71.4 to 75.2)266576.5(75.1 to 77.9)
Treatments in year following initial stroke (at least 2 prescriptions) (% of patients who survived at least 56 days)
 Anticoagulants54547.5(44.9 to 50.1)52934.8(32.8 to 36.9)107440.3(38.7 to 41.9)
 Antiplatelet drugs56649.3(46.7 to 52)80653.1(50.9 to 55.2)137251.5(49.8 to 53.1)
  • AF, atrial fibrillation; GP, general practitioner.